May 2024

We are very happy to announce a change in the inclusion criteria for the TUBA-WISP II study. From this point forward, also PALB2 PV carriers can be included. The other included pathogenic variants remain the same: BRCA1, BRCA2, RAD51C, RAD51D and BRIP1.

When PALB2 PV carriers are eligible for risk-reducing surgery, they can also participate in the TUBA-WISP II study. We recommend to consider for every individual patient whether or not the benefits of risk-reducing surgery outweigh the risks. This does not apply to all participating centers. 

March 2024

We are very happy to announce that we are currently halfway with inclusions. We have now included 1500 out of the intented 3000 participants!